What Causes Genital Warts: HPV Types and Transmission Factors

Human Papillomavirus (HPV)

Human papillomavirus (HPV) is a non‑enveloped, double‑stranded DNA virus that infects keratinocytes of cutaneous and mucosal epithelium. More than 200 genotypes have been identified, each designated by a number reflecting the order of discovery. The virus is species‑specific to humans and does not replicate in other animals.

HPV genotypes are grouped into low‑risk and high‑risk categories based on their oncogenic potential. Low‑risk types such as HPV‑6 and HPV‑11 are strongly associated with benign genital warts, whereas high‑risk types (e.g., HPV‑16, HPV‑18) are linked to cervical, anal, and oropharyngeal cancers. Both groups share a similar genome organization but differ in the activity of the E6 and E7 oncoproteins.

Epidemiologic surveys estimate that most sexually active adults acquire at least one HPV infection during their lifetime. The majority of infections are transient and cleared by the immune system within 12–24 months, but persistent infection with low‑risk types can lead to visible warts, while persistent high‑risk infection drives neoplastic progression.

Low‑Risk HPV Types (HPV‑6, HPV‑11)

Low‑risk HPV types are defined by their rare association with malignant transformation and their frequent isolation from exophytic genital warts (condylomata acuminata). HPV‑6 and HPV‑11 together account for approximately 90 % of all genital wart cases worldwide. These genotypes preferentially infect the stratified squamous epithelium of the anogenital region.

The clinical phenotype of low‑risk infection ranges from subclinical, flat lesions to large, cauliflower‑like growths that may cause discomfort, bleeding, or psychosocial distress. Because the viral genome remains episomal, integration into host chromosomes is uncommon, which explains the low malignant potential.

A concise comparison of the most relevant low‑risk genotypes is provided below.

Transmission Pathways

Sexual contact is the principal route for genital HPV transmission. Vaginal, anal, and oral intercourse allow direct contact between infected epithelium and susceptible mucosa. The virus can be transferred even when the source partner has no visible lesions, because subclinical shedding of virions occurs regularly.

Non‑penetrative skin‑to‑skin contact also transmits HPV. Genital rubbing, mutual masturbation, and sharing of contaminated sex toys have been documented as viable pathways. The virus survives briefly on moist surfaces, so fomite transmission, while rare, cannot be excluded in high‑prevalence settings.

Vertical transmission from mother to neonate can occur during passage through an infected birth canal. This route is responsible for juvenile‑onset recurrent respiratory papillomatosis, a condition caused almost exclusively by HPV‑6 and HPV‑11 acquired at delivery.

Host Factors Influencing Infection

Immune competence is the dominant determinant of whether an HPV exposure results in persistent infection or rapid clearance. Individuals with HIV infection, immunosuppressive therapy, or primary immunodeficiencies exhibit higher rates of wart persistence, larger lesion burden, and reduced response to treatment.

Microtrauma to the genital epithelium — such as microscopic abrasions from shaving, friction during intercourse, or pre‑existing inflammatory dermatoses — creates portals of entry that facilitate viral access to basal keratinocytes where the viral life cycle initiates.

Co‑infection with other sexually transmitted agents (e.g., Chlamydia trachomatis, herpes simplex virus) can modulate local cytokine milieus, potentially enhancing HPV replication or impairing local immune surveillance, thereby increasing wart acquisition risk.

Viral Life Cycle in Epithelium

HPV initiates infection by binding to heparan sulfate proteoglycans on the basal cell surface, followed by conformational changes that expose the secondary receptor, likely a growth factor receptor such as EGFR. The virion is internalized via endocytosis and traffics to the nucleus where the early promoter drives expression of E1, E2, E6, and E7 proteins.

E1 and E2 orchestrate viral genome replication as episomes in the dividing basal layer. As infected cells differentiate and migrate toward the surface, the late promoter activates L1 and L2 capsid protein synthesis, allowing assembly of infectious virions in the upper epithelial strata. This differentiation‑dependent program limits viral production to superficial layers, aiding immune evasion.

Latency refers to a state where the viral genome persists at low copy number without productive virion synthesis. Reactivation can occur when immune control wanes or when epithelial injury triggers basal cell proliferation, leading to recurrent wart outbreaks months or years after the initial episode.

Diagnosis and Clinical Presentation

Clinical diagnosis of genital warts is usually made by visual inspection. Typical lesions appear as flesh‑colored, pink, or hyperpigmented papules that may coalesce into plaques with a characteristic cauliflower surface. Acetic acid application (3–5 %) can highlight subclinical flat lesions by causing transient whitening (acetowhite epithelium).

When lesions are atypical, ulcerated, or resistant to therapy, a shave or punch biopsy provides histopathologic confirmation. Histology shows koilocytes — enlarged keratinocytes with perinuclear halos and hyperchromatic nuclei — along with papillomatosis and parakeratosis.

Molecular testing (PCR‑based HPV DNA detection or hybrid capture) can identify the specific genotype present. While not required for routine wart management, genotyping is useful in research settings, for counseling about oncogenic risk, and in evaluating vaccine impact.